000			01653 a2200469 4500
005			20250514232527.0
264		0	_c20051205
008			200512s 0 0 eng d
022			_a1352-0504
024	7		_a10.1111/j.1365-2893.2005.00608.x _2doi
040			_aNLM _beng _cNLM
100	1		_aTseng, Po-Lin
245	0	0	_aDeterminants of early mortality and benefits of lamivudine therapy in patients with hepatitis B virus-related decompensated liver cirrhosis. _h[electronic resource]
260			_bJournal of viral hepatitis _cJul 2005
300			_a386-92 p. _bdigital
500			_aPublication Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
650	0	4	_aAdenine _xanalogs & derivatives
650	0	4	_aAdult
650	0	4	_aAged
650	0	4	_aAntiviral Agents _xtherapeutic use
650	0	4	_aDrug Resistance, Viral _xgenetics
650	0	4	_aFemale
650	0	4	_aHepatic Encephalopathy
650	0	4	_aHepatitis B virus _xdrug effects
650	0	4	_aHepatitis B, Chronic _xcomplications
650	0	4	_aHumans
650	0	4	_aLamivudine _xtherapeutic use
650	0	4	_aLiver Cirrhosis _xdrug therapy
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aMutation
650	0	4	_aOrganophosphonates _xtherapeutic use
650	0	4	_aSurvival Analysis
650	0	4	_aTaiwan
700	1		_aLu, Sheng-Nan
700	1		_aTung, Hung-Da
700	1		_aWang, Jing-Houng
700	1		_aChangchien, Chi-Sin
700	1		_aLee, Chuan-Mo
773	0		_tJournal of viral hepatitis _gvol. 12 _gno. 4 _gp. 386-92
856	4	0	_uhttps://doi.org/10.1111/j.1365-2893.2005.00608.x _zAvailable from publisher's website
999			_c15642358 _d15642358